Storm brewing for MNCs in India, with price caps and compulsory licensing mooted

27 March 2019

Several multinationals in India continue to be sole sellers of certain cancer drugs even after product patents expire, with generic companies unwilling or unable to enter the market due to various barriers including manufacturing and regulatory.

An academic paper has found the market for anti-cancer drugs in India has become highly monopolized after Trade Related Aspects of Intellectual Property Rights (TRIPS), with 10 molecules cornering 59.4% market share from 2013-2015, and molecules with two brands having 65.3% total sales in the same period, reports The Pharma Letter’s India correspondent.

Citing examples of innovator companies who continue to dominate the Indian market even after patent expiry, the paper includes Janssen (Johnson & Johnson {NYSE: JNJ) for trabectedin; Roche (ROG: SIX) for tocilizumab; Bristol-Myers Squibb (NYSE: BMY) for abatacept; Pfizer (NYSE: PFE) for idarubicin and Novartis (NOVN: VX) for aliskiren.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK